MYGN
Price:
$13.65
Market Cap:
$1.24B
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tum...[Read more]
Industry
Medical - Diagnostics & Research
IPO Date
1995-10-06
Stock Exchange
NASDAQ
Ticker
MYGN
According to Myriad Genetics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -10.66. This represents a change of -42.92% compared to the average of -18.67 of the last 4 quarters.
The mean historical PE Ratio of Myriad Genetics, Inc. over the last ten years is 66.66. The current -10.66 PE Ratio has changed -1699.19% with respect to the historical average. Over the past ten years (40 quarters), MYGN's PE Ratio was at its highest in in the December 2018 quarter at 207.40. The PE Ratio was at its lowest in in the September 2018 quarter at -1116.00.
Average
66.66
Median
18.45
Minimum
-78.86
Maximum
439.24
Discovering the peaks and valleys of Myriad Genetics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.12%
Maximum Annual PE Ratio = 439.24
Minimum Annual Increase = -103.64%
Minimum Annual PE Ratio = -78.86
Year | PE Ratio | Change |
---|---|---|
2023 | -6.02 | -42.34% |
2022 | -10.44 | -86.76% |
2021 | -78.86 | 1.09% |
2020 | -6.60 | -103.64% |
2020 | 181.19 | -58.75% |
2019 | 439.24 | 2.12% |
2018 | 19.80 | -75.55% |
2017 | 80.96 | 373.57% |
2016 | 17.09 | -43.43% |
2015 | 30.22 | 80.68% |
The current PE Ratio of Myriad Genetics, Inc. (MYGN) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-31.77
5-year avg
15.86
10-year avg
66.66
Myriad Genetics, Inc.’s PE Ratio is less than Guardant Health, Inc. (-7.45), less than CareDx, Inc (-7.71), less than Invitae Corporation (-0.00), less than Castle Biosciences, Inc. (125.93), less than Sotera Health Company (53.33), less than Syneos Health, Inc. (16.61), greater than Neogen Corporation (-111.60), less than RadNet, Inc. (401.14), greater than Natera, Inc. (-93.39), less than Medpace Holdings, Inc. (28.79), less than Personalis, Inc. (-3.97), less than Qiagen N.V. (107.22), greater than Olink Holding AB (publ) (-96.25), less than Aclaris Therapeutics, Inc. (-5.57), greater than Exact Sciences Corporation (-50.88), greater than Illumina, Inc. (-13.54), greater than Twist Bioscience Corporation (-13.50),
Company | PE Ratio | Market cap |
---|---|---|
-7.45 | $3.84B | |
-7.71 | $1.12B | |
-0.00 | $5.44M | |
125.93 | $769.64M | |
53.33 | $3.78B | |
16.61 | $4.46B | |
-111.60 | $2.63B | |
401.14 | $5.38B | |
-93.39 | $21.39B | |
28.79 | $10.54B | |
-3.97 | $420.36M | |
107.22 | $9.94B | |
-96.25 | $3.24B | |
-5.57 | $206.44M | |
-50.88 | $10.91B | |
-13.54 | $21.41B | |
-13.50 | $2.86B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Myriad Genetics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Myriad Genetics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Myriad Genetics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Myriad Genetics, Inc. (MYGN)?
What is the highest PE Ratio for Myriad Genetics, Inc. (MYGN)?
What is the 3-year average PE Ratio for Myriad Genetics, Inc. (MYGN)?
What is the 5-year average PE Ratio for Myriad Genetics, Inc. (MYGN)?
How does the current PE Ratio for Myriad Genetics, Inc. (MYGN) compare to its historical average?